文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

诱导型一氧化氮合酶mRNA正义寡核苷酸联合人可溶性血栓调节蛋白改善部分肝切除后脓毒症模型大鼠的生存

COMBINATION THERAPY WITH A SENSE OLIGONUCLEOTIDE TO INDUCIBLE NITRIC OXIDE SYNTHASE MRNA AND HUMAN SOLUBLE THROMBOMODULIN IMPROVES SURVIVAL OF SEPSIS MODEL RATS AFTER PARTIAL HEPATECTOMY.
PubMed 文献 · Shock · 2023-05-05
一句话结论大鼠70%肝切除后LPS脓毒症模型中,SO1联合低剂量rTM较单用LPS显著提高生存率,并降低血清NO、抑制肝内iNOS mRNA及蛋白表达。

本研究在大鼠70%肝切除后48小时静脉注射LPS建立的脓毒症休克模型中,评估iNOS mRNA正义寡核苷酸SO1与人重组可溶性血栓调节蛋白(rTM)低剂量联合治疗的保肝作用。SO1与LPS同时静脉注射,rTM在LPS前1小时静脉注射。与既往报道一致,SO1提高LPS注射后生存率;rTM与SO1联用不干扰SO1效应,且较单用LPS显著提高生存率。联合治疗降低血清NO水平,抑制肝内iNOS mRNA和蛋白表达及iNOS AS转录本表达,下调炎症和促凋亡基因、上调抗凋亡基因,并减少髓过氧化物酶阳性细胞数。作者认为SO1与rTM联合对脓毒症具有治疗潜力。

要点

  • 大鼠70%肝切除后48小时静脉注射LPS建立脓毒症休克模型,SO1与LPS同时静脉注射,rTM于LPS前1小时静脉注射。
  • SO1单用可提高LPS注射后生存率,与既往报道一致。
  • rTM与SO1联用不干扰SO1效应,且较单用LPS显著提高生存率。
  • 联合治疗降低血清NO水平,抑制肝内iNOS mRNA和蛋白表达,并降低iNOS AS转录本表达。
  • 联合治疗下调炎症和促凋亡基因mRNA、上调抗凋亡基因mRNA,并减少髓过氧化物酶阳性细胞数。

适用人群与场景

  • 大鼠70%肝切除后48小时静脉注射LPS建立的脓毒症休克模型。

处置流程与药物剂量

  • SO1与LPS同时静脉注射;rTM在LPS注射前1小时静脉注射,为低剂量。

研究设计与关键结果

  • 研究类型:大鼠脓毒症休克模型实验;动物行70%肝切除,48小时后静脉注射LPS。
  • 干预与对照:SO1与LPS同时静脉注射,rTM于LPS前1小时静脉注射;对照为单用LPS。
  • 主要终点:SO1单用提高LPS注射后生存率,与既往报道一致;rTM与SO1联用不干扰SO1效应,且较单用LPS显著提高生存率。
  • 机制指标:联合治疗降低血清NO水平,抑制肝内iNOS mRNA和蛋白表达,降低iNOS AS转录本表达。
  • 基因表达:联合治疗下调炎症和促凋亡基因mRNA表达,上调抗凋亡基因mRNA表达。
  • 组织学:联合治疗减少髓过氧化物酶阳性细胞数。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠脓毒症休克模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为SO1与rTM联合对脓毒症具有治疗潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis after a major hepatectomy is a critical problem. In septic shock, the inflammatory mediator, nitric oxide (NO), is overproduced in hepatocytes and macrophages. The natural antisense (AS) transcripts, non-coding RNAs, are transcribed from a gene that encodes inducible nitric oxide synthase (iNOS). iNOS AS transcripts interact with and stabilize iNOS mRNAs. A single-stranded "sense oligonucleotide" (designated as SO1) corresponding to the iNOS mRNA sequence inhibits mRNA-AS transcript interactions and reduces iNOS mRNA levels in rat hepatocytes. In contrast, recombinant human soluble thrombomodulin (rTM) treats disseminated intravascular coagulopathy by suppressing coagulation, inflammation, and apoptosis. In this study, the combination therapy of SO1 and a low dose of rTM was evaluated for hepatoprotection in a rat septic shock model after partial hepatectomy. Rats underwent 70% hepatectomy, followed by intravenous (i.v.) injection of lipopolysaccharide (LPS) after 48 h. SO1 was injected (i.v.) simultaneously with LPS, whereas rTM was injected (i.v.) 1 h before LPS injection. Similarly to our previous report, SO1 increased survival after LPS injection. When rTM, which has different mechanisms of action, was combined with SO1, it did not interfere with the effect of SO1 and showed a significant increase in survival compared with LPS alone treatment. In serum, the combined treatment decreased NO levels. In the liver, the combined treatment inhibited iNOS mRNA and protein expression. A decreased iNOS AS transcript expression by the combined treatment was also observed. The combined treatment decreased mRNA expression of the inflammatory and pro-apoptotic genes while increasing that of the anti-apoptotic gene. Furthermore, the combined treatment reduced the number of myeloperoxidase-positive cells. These results suggested that the combination of SO1 and rTM has therapeutic potential for sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Nakatake R, Okuyama T, Kotsuka M, et al. COMBINATION THERAPY WITH A SENSE OLIGONUCLEOTIDE TO INDUCIBLE NITRIC OXIDE SYNTHASE MRNA AND HUMAN SOLUBLE THROMBOMODULIN IMPROVES SURVIVAL OF SEPSIS MODEL RATS AFTER PARTIAL HEPATECTOMY. Shock. 2023. PMID: 37141168. doi:10.1097/SHK.0000000000002135

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。